Kronos Bio, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 28 rows in 2024. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2024-10-15: Reporting owner Frisbee Allison; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-10-15: Reporting owner Lin Charles Y; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-06-25: Reporting owner Ridloff Elena; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2024-06-25: Reporting owner DANSEY ROGER D; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2024-10-15 | Frisbee Allison Officer (Chief Administrative Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +72,900 72,900 owned after | $0.96 exercise price | 2024-10-15 | |
| 2024-10-15 | Lin Charles Y Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +72,900 72,900 owned after | $0.96 exercise price | 2024-10-15 | |
| 2024-06-25 | Ridloff Elena Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | DANSEY ROGER D Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | Stultz Katherine V Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | Yang Taiyin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | Blunt Roshawn A. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | Kazam Joshua A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | Belldegrun Arie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-25 | TANEN DAVID M Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $0.95 exercise price | 2024-06-26 | |
| 2024-06-03 | KNOBELMAN DEBORAH Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +246,390 246,390 owned after | $0.75 exercise price | 2024-06-04 | |
| 2024-02-23 holding as of filing | Olek Elizabeth A Officer (SR VP, CLINICAL SCIENCE) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.99 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Olek Elizabeth A Officer (SR VP, CLINICAL SCIENCE) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.02 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Olek Elizabeth A Officer (SR VP, CLINICAL SCIENCE) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.09 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Olek Elizabeth A Officer (SR VP, CLINICAL SCIENCE) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.08 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Lin Charles Y Officer (SR VP, RESEARCH & DEVELOPMENT) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.53 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Lin Charles Y Officer (SR VP, RESEARCH & DEVELOPMENT) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $28.82 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Lin Charles Y Officer (SR VP, RESEARCH & DEVELOPMENT) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $7.08 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Lin Charles Y Officer (SR VP, RESEARCH & DEVELOPMENT) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.09 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Lin Charles Y Officer (SR VP, RESEARCH & DEVELOPMENT) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.08 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $13.35 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $28.82 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $7.08 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $4.32 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $5.02 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $2.09 exercise price | 2024-02-23 | ||
| 2024-02-23 holding as of filing | Frisbee Allison Officer (SR VP, CORP OPERATIONS & LEGAL) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.08 exercise price | 2024-02-23 | ||
| 2024-02-15 | BISCHOFBERGER NORBERT W Director, Officer (PRESIDENT & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +699,800 699,800 owned after | $1.08 exercise price | 2024-02-16 |